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Degradation of the surrounding extracellular matrix (ECM) by matrix metalloproteinases (MMPs) drives
invasion and metastasis of cancer cells. We previously demonstrated that tetraspanin CD9 expression
upregulates pro-MMP-9 expression and release and promotes cellular invasion in a human ﬁbrosarcoma
cell line (HT1080). These events were dependent upon the highly functional second extracellular loop of
CD9.We report here that the epidermal growth factor receptor (EGFR) tyrosine kinase expression and activ-
ity are involved in the CD9-mediated increase in pro-MMP-9 release and cellular invasion. Pro-MMP-9
expression was signiﬁcantly decreased in a dose-dependent manner using ﬁrst a broad spectrum receptor
tyrosine kinase inhibitor andmultiple speciﬁc EGFR inhibitors in CD9-HT1080 cells. Furthermore, geﬁtinib
treatment of CD9-HT1080 cells reduced invasion through matrigel. EGFR knockdown using short interfer-
ing RNA resulted in decreased pro-MMP-9 expression and release into the media and subsequent cellular
invasion without affecting CD9 expression or localization. Conclusively, this study points to EGFR as a key
mediator between CD9-mediated pro-MMP-9 release and cellular invasion of HT1080 cells.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Cancer cell invasion is initiated by matrix metalloproteinase
(MMP) degradation of the surrounding extracellular matrix. This
process has been extensively researched and subsequently broad
spectrum inhibitors were developed to regulate MMP activity
in vivo. However, these inhibitors demonstrated lack of clinical efﬁ-
cacy and studies were discontinued primarily because pharmaco-
logical intervention after metastasis had occurred was ineffective
[1–3]. Interest in MMP research has since shifted to ﬁnding other
ways to regulate their expression, release, and activity prior to
metastasis. We recently established that expression of tetraspanin
CD9 in a highly invasive human ﬁbrosarcoma cell line (HT1080)
speciﬁcally augmented the expression and release of a prominent
member of the MMP family, pro-MMP-9 [4]. This current study
aimed to clarify how CD9 may regulate MMP-9 expression.Tetraspanins have been implicated in numerous cellular func-
tions including proliferation, migration, and invasion [5]. We pre-
viously demonstrated that the highly functional second
extracellular loop (EC2) of CD9 was necessary for pro-MMP-9
secretion and subsequent cellular invasion [4]. CD9 EC2 is respon-
sible for a myriad of functions including association with heparin-
binding epidermal growth factor-like growth factor [6,7], cell
motility [8,9], cell adhesion and ﬁbronectin matrix assembly [10],
association with other tetraspanins and integrins [11], and associ-
ation with TGFa [12]. Interestingly, CD9 has also been demon-
strated to associate with epidermal growth factor (EGF) receptor
(EGFR) and regulate its activity; however, the mechanisms associ-
ated with CD9 regulation of EGFR are not entirely clear. Murayama
et al. [13] demonstrated that the EC2 of CD9 associates with EGFR
and b1 integrin. Treatment with an anti-CD9 monoclonal antibody,
ALB6, enhanced EGFR internalization after EGF treatment [13].
ALB6 has been reported as an inhibitory antibody to CD9 [14,15];
therefore, inhibition of CD9 resulted in increased EGFR internaliza-
tion. In the same study, CD9 and EGFR expression in Chinese
hamster ovary cells (CHO) resulted in increased receptor internal-
ization upon EGF treatment [13]. Hence, the role of CD9 in EGFR
regulation is uncertain due to that fact that both inhibition and
overexpression had similar effects. Moreover, there is evidence
for a lack of association between CD9 and EGFR when CD9 is
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EGFR activation via its association with transmembrane TGFa in a
juxtacrine manner while negatively affecting autocrine TGFa
signaling [12].
In a HT1080model system, CD9 was earlier demonstrated to co-
immunoprecipitate with EGFR [16]. Multiple reports suggest that
EGFR is strongly connected to the augmentation of MMP-9 expres-
sion [17–20]. Because in our studies the absence of CD9 EC2
resulted in an absence of MMP-9 expression, release, and subse-
quent invasion [4], we hypothesized that EGFR may regulate
MMP-9 expression in HT1080 cells. We used multiple EGFR tyro-
sine kinase inhibitors (TKIs) and siRNA directed to EGFR to explore
this phenomenon. We conclude that CD9-mediated pro-MMP-9
expression and release and subsequent cell invasion are dependent
upon EGFR expression and activity in HT1080 cells.2. Materials and methods
2.1. Reagents and antibodies
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), fetal bovine
serum (FBS) penicillin–streptomycin, Geneticin (G418), human
plasma ﬁbronectin (FN), and phosphate buffered saline (PBS; pH
7.4) were purchased from Gibco (Grand Island, NY). Antibodies to
anti-human CD9 (mAb7) were generated in our laboratory as pre-
viously described [21]. Anti-IgG (M9269), anti-human b-tubulin
(T2200), and FITC-conjugated anti-mouse (F2012) antibodies were
purchased from Sigma Aldrich (St. Louis, MO). The anti-EGFR
antibody (4267) was purchased from Cell Signaling Technologies
(Danvers, MA). The horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies anti-rabbit (NA934VS) and anti-mouse
(NA931VS) were purchased from GE Healthcare (Pittsburgh, PA).
Receptor tyrosine kinase inhibitors sunitinib (S-8803), geﬁtinib
(G-4408), erlotinib (E-4997), lapatinib (L-4804) and AG1478
(T-7310) were purchased from LC laboratories (Woburn, MA).
Matrigel from Engelbreth-Holm-Swarm mouse tumor and 8.0 lm
pore cell culture inserts were purchased from BD Biosciences
(Bedford, MA). Lipofectamine 2000 transfection reagent was
purchased from Invitrogen (Carlsbad, CA).
2.2. Cell culture
Mock and CD9 HT1080 cells were generated as previously de-
scribed and cultured in DMEM supplemented with 10% FBS, 1%
penicillin–streptomycin, and 0.75 mg/ml G418 in a humidiﬁed,
5% CO2, 37 C incubator [4]. For each experiment, FN was diluted
to 10 lg/ml in PBS and 2 ml was added to each well of 6-well cell
culture dishes and allowed to incubate at 37 C for 3 h. The FN-PBS
solution was then aspirated and any residual solution was washed
with PBS. Subconﬂuent HT1080 cells were harvested, counted, and
suspended as 5.0  105 cells/ml in serum-free (SF) DMEM.
1.0  106 cells were added to each FN-coated well in a ﬁnal volume
of 2 ml of SF DMEM and allowed to incubate for 24 h before the
media was collected and the cells were harvested.
2.3. Western blot analysis
Cell lysates were harvested using TX-100 lysis buffer (1% TX-
100, 20 mM Tris–HCl, 150 mM NaCl, 0.5% deoxycholate, and 0.1%
sodium dodecyl sulfate) including protease and phosphatase inhib-
itor cocktails purchased from Sigma Aldrich. Lysate concentration
was determined using a colorimetric Bradford Assay and a stan-
dard curve. Equal concentrations of lysate mixed with reducing
or non-reducing buffer were loaded onto a 12.5% SDS–polyacryl-
amide gel. The proteins were transferred to a polyvinyl diﬂuoridemembrane and non-speciﬁc sites of binding were blocked using
5% BSA in Tris-buffered saline with 1% Tween-20 (TBST) solution.
Anti-human CD9 (mAb7, 1:500), and-human total EGFR (1:5000),
or anti-human b-tubulin (1:20,000) were diluted in 5% BSA-TBST
and incubated overnight at 4 C. After washing off the primary
antibody with TBST, a HRP-conjugated anti-mouse antibody
(1:5000) for mAb7 or anti-rabbit antibody (1:50,000) for EGFR
and b-tubulin were diluted in 5% BSA-TBST, added to the blots,
and incubated for 1 h at room temperature. The blots were again
washed as described earlier and incubated with Pierce ECL 2 Wes-
tern blotting substrate (80196, Thermo Scientiﬁc, Rockford, IL) for
5 min. X-ray ﬁlm was used to detect chemiluminesence, and the
ﬁlms were developed using a Konica Minolta X-ray machine. Band
density was determined using NIH Image J software, and mAb7
band densities were normalized the corresponding to b-tubulin
band densities.
2.4. Receptor tyrosine kinase inhibitor treatment
Each inhibitor was reconstituted in DMSO to the following stock
concentrations: sunitinib 50 lM, geﬁtinib 100 lM, erlotinib
100 lM, lapatininb 100 lM, and AG1478 100 lM. These stock con-
centrations were further diluted using DMSO and added to the
2 ml of SF DMEM and the cell mixture to get a ﬁnal concentration
of 10, 5, or 1 lM inhibitor with an equivalent ﬁnal volume of DMSO
for each treatment. Likewise, the same volume of DMSO without
inhibitor was added to the cells as a negative control. The cells
and DMSO or diluted inhibitor were incubated for 30 min at
37 C, then added to the FN-coated wells and placed in the incuba-
tor for 24 h. After 24 h, no difference in cell conﬂuence was ob-
served between the different treatments.
2.5. Gelatin zymography
Gelatin zymography was performed exactly as previously de-
scribed [4]. Relative density was calculated by dividing by the
pro-MMP-9 band in the Mock treatment lane. A minimum of three
independent experiments were performed for quantiﬁcation of rel-
ative band density.
2.6. RNA extraction and qRT-PCR analysis
Forward and reverse primers for CD9 and MMP-9 were previ-
ously described [4]. EGFR forward: CATGTCGATGGACTTCCAGA
and reverse: GGGACAGCTTGGATCA CACT primers were designed
using Universal Probe Library primer design tool and purchased
from Sigma Aldrich. Total RNA from Mock- and CD9-HT1080 cells
was harvested and analyzed exactly as previously described [4].
Sample tests were run in triplicate, and the resulting average cycle
threshold (CT) values were normalized to cyclophilin-D house-
keeping gene, and fold changes in mRNA expression were calcu-
lated using the DDCt method as described [4].
2.7. Flow cytometry
Mock- and CD9-HT1080 cells were harvested and suspended at
5.0  105 cells/ml in 5% goat serum-DMEM (blocking media) and
incubated on ice for 45 min. All subsequent antibody incubations
were performed on ice. Primary antibody was added (5 lg/ml)
and incubated for 1 h. Unbound primary antibody was removed
by washing the cells three times. Brieﬂy, the cells were pelleted
(800  g for 5 min), the supernatant was discarded, and the cell
pellet was suspended using 1 ml of ice-cold PBS (pH 7.4). The cells
were incubated with secondary FITC-conjugated antibody (5 lg/
ml) in blocking media for 1 h. The secondary antibody was re-
moved by washing, and the cells were suspended in PBS for data
Fig. 1. CD9-HT1080 cells release less pro-MMP-9 after treatment with a broad
spectrum receptor tyrosine kinase inhibitor sunitinib. (A) The expression of CD9 in
HT1080 cells was assessed by Western blot analysis. (B) Pro-MMP-9 release into
serum-free media of HT1080 cells plated on 10 lg/ml FN for 24 h was measured
using gelatin zymography as described in Section 2. Gelatinolytic activity was
quantitated by measuring band intensity over three independent repeats. Data are
presented as mean ± SD (⁄⁄p < 0.01).
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Calibur ﬂow cytometer equipped with Cell Quest Pro
software (Becton–Dickinson, Bedford, MA). The geometric mean
ﬂuorescence intensity values were averaged among three or more
independent experiments.
2.8. Matrigel invasion assay
Matrigel invasion assays were performed exactly as previously
described [4]. Cells were counted in 10 random ﬁelds of view per
membrane and averaged.
2.9. Knockdown of EGFR
Small interfering RNA (siRNA) targeting EGFR was ordered from
Cell Signaling Technology (#6480). A non-speciﬁc, scrambled siR-
NA (AM4635) purchased from Ambion (Life Technologies, Grand
Island, NY) was used as a control. Prior to transfection, 10 ll of
Lipofectamine 2000 was incubated in 0.5 ml of serum-free SmBM
for 5 min at room temperature, then 600 pmol of siRNA in 0.5 ml
of serum-free SmBM was added to Lipofectamine dilution and al-
lowed to incubate for 20 min. HT1080 cells were 70% conﬂuent
upon transfection, cell monolayers were washed three times with
PBS, then 1 ml of Lipofectamine-siRNA mixture was added
drop-wise to cells in 6-well cell culture plates. After 6 h, the
mixture was aspirated and monolayers were rinsed with serum-
supplemented SmBM and allowed to incubate for 24–48 h before
preforming experiments.
2.10. Statistical analysis
Experiments were repeated at least three independent times.
Statistical analysis was carried out using SPSS software, and graphs
were generated using GraphPad Prism 6 software. The bars repre-
sent the mean, and error bars represent the standard deviation
from the mean. An independent samples t-test or Mann–Whitney
U Test was used to compare two means. Analysis of Variance
(ANOVA) was used to compare three or more means of normally
distributed homogenous data. Tukey’s HSD post hoc analysis was
conducted to determine any difference among the groups. Welch’s
ANOVA was used for three sample means with non-normally dis-
tributed data, and Dunnet’s T3 post hoc analysis was used to deter-
mine any difference among these means. P values less than 0.05
were considered statistically signiﬁcant.
3. Results
3.1. Inhibition of EGFR signaling results in decreased pro-MMP-9
release from CD9-HT1080 cells
Our laboratory previously reported the successful cell surface
expression of tetraspanin CD9 in human ﬁbrosarcoma cells that
endogenously express low levels of CD9 [4]. The expression of
CD9 in CD9-HT1080 cells was conﬁrmed using an anti-human
CD9 monoclonal antibody in Western blot (Fig. 1A). The presence
of CD9 in the Mock-HT1080 cells was only evident upon prolonged
blot exposure (data not shown). CD9-mediated increased expres-
sion and release of pro-MMP-9 were also previously demonstrated
[4]. This observed increase in pro-MMP-9 release via gelatin
zymography was signiﬁcantly attenuated upon treatment of the
cells with a broad spectrum tyrosine kinase inhibitor, sunitinib,
and was dose-dependent (Fig. 1B). Quantiﬁcation of gelatin degra-
dation revealed a signiﬁcant decrease in CD9-HT1080 cells treated
with sunitinib at 5 and 10 lM concentrations.
We further explored the role of EGFR in pro-MMP-9
release using multiple tyrosine kinase inhibitors with previouslydemonstrated speciﬁcity for EGFR. Getﬁtnib, erlotinib, lapatinib,
and AG1478 all demonstrated a dose-dependent inhibition of
pro-MMP-9 release in CD9-HT1080 cells (Fig. 2A–D). Moreover,
CD9-HT1080 cells were signiﬁcantly less invasive through matrigel
after treating with 10 lM of geﬁtinib (Fig. 2E). These ﬁndings show
that CD9 augments pro-MMP-9 release and subsequent cell inva-
sion through matrigel via EGFR activation.
3.2. Knockdown of EGFR in CD9-HT1080 cells attenuates the release of
pro-MMP-9 and subsequent cell invasion
EGFR expression is strongly correlated to increased expression
and release of MMP-9 [22,23]. Upon discovering that inhibiting
Fig. 2. Epidermal growth factor receptor tyrosine kinase inhibitors reduce the
expression of pro-MMP-9 and inhibit CD9-HT1080 cell invasion. (A–D) Pro-MMP-9
gelatinolytic activity of Mock and CD9-HT1080 cells treated with DMSO or EGFR
speciﬁc tyrosine kinase inhibitors geﬁtinib, erlotinib, lapatinib, and AG1478,
respectively, was measured after 24 h on FN using gelatin zymography and
quantitated after three independent repeats. Data are presented as mean ± SD
(⁄p < 0.05, ⁄⁄p < 0.05). (E) Representative images of matrigel invasion assays used to
assess cellular invasion in Mock and CD9-HT1080 cells treated with DMSO or
geﬁtinib after 20 h. Cells that invaded through matrigel were ﬁxed and stained with
crystal violet. Quantitation of the number of invasive cells per ﬁeld of view is
presented in the bar graph below (⁄⁄p < 0.05).
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in pro-MMP-9 release observed in CD9-HT1080 cells, we explored
if silencing EGFR affected pro-MMP-9 levels. We used siRNA direc-
ted against EGFR to knock down EGFR expression in CD9-HT1080
cells and a scrambled (Ctr) siRNA for a control treatment. The
mRNA and protein levels of CD9 were not affected by Ctr or EGFR
siRNA treatment. However, total EGFR mRNA levels were signiﬁ-
cantly decreased in the EGFR siRNA treated CD9-HT1080 cells
and were not affected upon treatment with Ctr siRNA (Fig. 3A).
MMP-9 mRNA levels were also signiﬁcantly decreased in the EGFR
siRNA treated CD9-HT1080 cells compared to the Ctr siRNA treated
CD9-HT1080 cells (Fig. 3A). The protein levels of CD9 in the CD9-
HT1080 cells were unaffected by treatment with EGFR siRNA
(Fig. 3B). Total EGFR levels were similar between the Mock and
CD9-HT1080 cells treated with Ctr siRNA, but were less in CD9-
HT1080 cells treated with EGFR siRNA. Because CD9 and EGFR
were demonstrated to co-immunoprecipate from HT1080 cells
[16], we accessed whether any changes in the cell surface expres-
sion of CD9 occurred upon knockdown of EGFR. Flow cytometry
was used to assess CD9 cell surface expression levels upon treat-
ment with Ctr and EGFR siRNA in both Mock and CD9-HT1080
cells. There were no signiﬁcant differences in CD9 expression as
a consequence of EGFR knockdown in CD9-HT1080 cells (Fig. 3C).
Therefore, we attribute any phenotypic changes to total EGFR
expression levels and not to changes in CD9 expression or
localization.
Pro-MMP-9 release into the media and cell invasion were as-
sessed after treatment with Ctr and EGFR siRNA using gelatin
zymography and a matrigel invasion assay, respectively. Upon
knockdown of EGFR, there were signiﬁcantly decreased levels of
pro-MMP-9 released into the media of cells as demonstrated by
gelatin degradation (Fig. 3D). Furthermore, the CD9-HT1080 cells
lacking EGFR were signiﬁcantly less invasive than their Ctr siRNA
treated CD9-HT1080 cells (Fig. 3E). These results indicated that
the absence EGFR in CD9-HT1080 cells was sufﬁcient to decrease
MMP-9 mRNA and protein levels, and this absence reduced
CD9-HT1080 invasion without affecting the mRNA, protein, or cell
surface levels of CD9.4. Discussion
It is well-established that EGFR activation results in increased
MMP-9 expression and release [20,22] and that MMP-9 expres-
sion results in increased cell invasion [23,24]. However, the
mechanism for how CD9 may regulate MMP-9 expression is not
entirely clear. There are indications that CD9 directly associates
with and downregulates EGFR signaling by facilitating the rate
of receptor internalization after ligand binding [13]. This ﬁnding
was confused by the fact that an inhibitory antibody to CD9,
ALB6, and CD9 overexpression had the same outcome [13]. Fur-
thermore, another group demonstrated that CD9 did not associ-
ate with EGFR, but regulated EGFR juxtacrine signaling by
associating with the transmembrane EGFR ligand TGFa [12]. This
report showed that CD9 regulated the release of pro-MMP-9 in
HT1080 cells via EGFR expression and activity. We conﬁrmed this
ﬁnding and now are the ﬁrst to demonstrate conclusively that
EGFR activity is necessary for the augmented pro-MMP-9 re-
leased and regulated by CD9 expression using four distinct EGFR
tyrosine kinase inhibitors. All inhibitors demonstrated a dose-
dependent inhibition of pro-MMP-9 indicating their speciﬁcity.
Treatment with 10 lM geﬁtinib inhibited pro-MMP-9 release to
a level comparable to Mock-HT1080 cells. Consequently, we
demonstrated same concentration of geﬁtinib resulted in the
suppression of CD9-HT1080 cell invasion to the level of Mock-
HT1080 cells. Therefore, inhibition of EGFR activity is sufﬁcient
Fig. 3. Knockdown of EGFR results in decreased pro-MMP-9 expression and release without affecting the expression or localization of CD9. (A) The fold change in mRNA
expression of CD9, EGFR, and MMP-9 in Mock- and CD9-HT1080 cells treated with Ctr or EGFR siRNA was measured using qRT-PCR. (B) Protein expression of CD9 and total
EGFR expression was measured using Western blot analysis of Mock- and CD9-HT1080 cell lysates treated with Ctr or EGFR siRNA. (C) Flow cytometric analysis of
nonpermeabilized Mock- and CD9-HT1080 cells for CD9 expression after treatment with Ctr or EGFR siRNA. Dotted line represents non-speciﬁc mIgG binding, light-gray
shaded histogram is mAb7 (anti-CD9) staining of Mock + Ctr siRNA, dark gray shaded histogram is mAb7 staining of CD9 + Ctr siRNA, and the solid line unshaded histogram is
mAb7 staining of CD9 + EGFR siRNA. (D) Pro-MMP-9 release into the cell media after treatment with Ctr or EGFR siRNA was assessed using gelatin zymography. (E) Matrigel
invasion assay of Mock- and CD9-HT1080 cells after treatment with Ctr or EGFR siRNA and quantiﬁcation of the average number of cells that invaded per ﬁeld of view. Bar
graphs represent mean ± SD (⁄p < 0.01, ⁄⁄p < 0.05).
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invasion in CD9-HT1080 cells.
The expression of total EGFR in Mock, CD9, andD6 HT1080 cells
was not signiﬁcantly different (Fig. 3B; unpublished observations).
Therefore, the regulation of the EGFR signaling is either at the cell
surface level of the receptor or at the level of EGFR phosphoryla-
tion. Our experimental design of plating the cells on ﬁbronectin
in serum-free media was similar to other studies that demon-
strated ECM-mediated activation of EGFR in the absence of EGFR
ligands [25]. We have established that CD9 associates with integrin
a5b1 in multiple cell lines and that it plays a role in regulating the
activation state of b1 integrins [26,27]. Therefore, we hypothesize
full-length CD9 expression may stabilize CD9-a5b1 interactions
with ﬁbronectin and augment intergrin-mediated EGFR activation
to stimulate increased pro-MMP-9 release. Consequently, in the
absence of CD9 (Mock-HT1080 cells) or when CD9 is not associated
with a5b1 integrin (D6-HT1080 cells), pro-MMP-9 expression and
release or cell invasion is not increased over baseline invasion [4].
The same results are observed when we inhibit EGFR activation
using EGFR tyrosine kinase inhibitors or decrease the expression
of EGFR. Consequently, we propose that CD9 regulates EGFR signal-
ing in HT1080 cells by a CD9-a5b1-FN interaction that stimulates
EGFR phosphorylation.In conclusion, our results demonstrate that the activation of
EGFR is necessary for the increase in both pro-MMP-9 release
and migration observed in CD9-HT1080 cells. Although EGFR
inhibitors have previously been implicated to decrease pro-MMP-
9 expression and release, this is the ﬁrst study to use multiple EGFR
speciﬁc inhibitors to demonstrate this effect in a dose-dependent
manner. Additionally, we conﬁrmed that the expression of EGFR
was necessary for pro-MMP-9 expression and release and subse-
quent cell invasion. This ﬁnding has clinical implications as
MMP-9 and EGFR coexpression was positively correlated with a
poor prognosis in human non-small cell lung cancer (NSCLC) biop-
sies [17]. We suggest that screening for CD9 expression in conjunc-
tion with MMP-9 and EGFR in NSCLC biopsies may signiﬁcantly
improve the prognostic value as CD9 expression has also been
implicated in NSCLC malignancies [28,29].
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